Table 1. Demographic and clinical characterization of peanut-sensitized patients from Africa and Sweden, as well as Swedish peanut tolerant patients.
| Zimbabwe tolerant n = 54 | Sweden tolerant n = 25 | Sweden allergic n = 25 | |
|---|---|---|---|
| Age, years: median (range) | 11 (0.9–59) | 11 (3–18) | 9 (3–15) |
| Sex (m/f) | (31/23) | (13/12) | (13/12) |
| Skin prick test or IgE positive | |||
| HDM (n) | 34 | 3 | 1 |
| Pollens (n) | 35 | 25 | 18 |
| Animals (n) | 16 | 15 | 13 |
| Food (n) | 32 | 24 | 12 |
| Peanut IgE (kUA/l) median (range) | 2.5 (0.1–200) | 2.8 (0.23–17) | 280 (28–1300) |
| Total IgE (kU/l) median (range) | 520.5 (23–20000) | 290 (33.9–2398) | 647 (105–4096) |
| Asthma (n /%) | 15 (28) | 18 (72) | 18 (72) |
| Rhinitis/Conjunctivitis (n /%) | 28 (52) | 22 (88) | 12 (48) |
| Skin symptoms*(n /%) | 39 (72) | 9 (36) | 12 (48) |
| GI symptoms†(n /%) | 5 (9) | 2 (8) | 2 (8) |
Skin prick test (SPT) positive ≥3 mm. Peanut IgE ≥ 0.1 kUA/l. Total IgE ≥ 2 kU/l. (n) number of patients, (n /%) number and percentage of patients.
*
Skin symptoms: dermatitis, eczema, urticaria, angioedema.
†
GI symptoms: vomiting, bloating, abdominal discomfort.